Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00142220
Other study ID # OMEGAVEN
Secondary ID
Status Completed
Phase Phase 4
First received August 31, 2005
Last updated September 8, 2006
Start date January 2004

Study information

Verified date September 2006
Source University Medicine Greifswald
Contact n/a
Is FDA regulated No
Health authority Germany: Ethics Commission
Study type Interventional

Clinical Trial Summary

We study whether an increased proportion of omega-3-fatty acids (contained in fish oil) in the nutrition of critically ill patients reduces systemic inflammation.


Recruitment information / eligibility

Status Completed
Enrollment 160
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- indication for parenteral nutrition

Exclusion Criteria:

- hypertriglyceridemia

- coagulation disorder

- decompensated liver cirrhosis or acute liver failure

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Defined percentage of omega-3-fatty acids


Locations

Country Name City State
Germany Internistische ITS Greifswald

Sponsors (2)

Lead Sponsor Collaborator
University Medicine Greifswald Fresenius AG

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary level of IL-6 in serum
Primary HLA-expression on monocytes
Secondary number of nosocomial infections
Secondary days on mechanical ventilation
Secondary duration of ICU stay
Secondary mortality
Secondary SOFA score
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04560842 - The Efficacy of High-flow Nasal Cannula Oxygen Therapy in Sepsis Patients N/A
Completed NCT04475081 - Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis Phase 3
Completed NCT03314831 - The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis
Completed NCT03371680 - Kinetics of Surfactant Proteins, Phosphatidylcholine and Body Water in Intensive Care Unit (ICU) N/A
Completed NCT00046072 - A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis Phase 2
Enrolling by invitation NCT05602584 - Effect of Immunophenotype on Prognosis of Sepsis
Completed NCT06338111 - Can we Improve Mortality Prediction in Patients With Sepsis in the Emergency Department
Completed NCT04292431 - Leukocyte MOrphology and CORticosteroids Response in SEPtic Patients (MOCORSEP)
Recruiting NCT03472170 - Clinical Trial for Valuation of the Effectiveness of Lactoferrine in the Prevention of Sepsis in New Premature Born. Bimonitorization of the Antinflammatory Mechanisms, Antioxidants and the Intestinal Microbiote. N/A
Not yet recruiting NCT05382078 - Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients
Recruiting NCT03956043 - Diagnostic Accuracy in Sepsis
Recruiting NCT05977153 - CT for Personalized Mechanical Ventilation N/A
Completed NCT00448968 - The Utility of Ischemia Modified Albumin (IMA) in Sepsis N/A
Completed NCT05246969 - Detecting Sepsis in Patients With Severe Subarachnoideal Hemorrhage
Not yet recruiting NCT06446947 - Identification of Markers of Poor Clinical Prognosis in Sepsis by Epigenetic Analysis
Recruiting NCT05261607 - Analysis of the Evolution of Mortality in an Intensive Care Unit
Recruiting NCT04203979 - Sepsis: From Syndrome to Personalized Care
Recruiting NCT03990467 - Observed Pharmacokinetic of Piperacillin/Tazobactam Compared to Amikacin in ICU N/A
Recruiting NCT05338359 - Metrology to Enable Rapid and Accurate Clinical Measurements in Acute Management of Sepsis
Completed NCT02562261 - Platelet REactivity in Sepsis Syndrome (PRESS)